newsfilter
← Latest News
Business Wire·

2seventy bio Reports Fourth Quarter and Full Year 2024 Financial Results

Entered into definitive merger agreement to be acquired by Bristol Myers Squibb at a price of $5.00 per share in an all-cash transaction; expected to close in the second quarter of 2025 Abecma generated $242 million